AP-2α inhibits hepatocellular carcinoma cell growth and migration

Huang,Wenhuan; Chen,Cheng; Liang,Zhongheng; Qiu,Junlu; Li,Xinxin; Hu,Xiang; Xiang,Shuanglin; Ding,Xiaofeng; Zhang,Jian

doi:10.3892/ijo.2016.3318

AP-2α inhibits hepatocellular carcinoma cell growth and migration

Authors:
- Wenhuan Huang
- Cheng Chen
- Zhongheng Liang
- Junlu Qiu
- Xinxin Li
- Xiang Hu
- Shuanglin Xiang
- Xiaofeng Ding
- Jian Zhang
View Affiliations

Affiliations: Key Laboratory of Protein Chemistry and Development Biology of State Education Ministry of China, College of Life Science, Hunan Normal University, Changsha, Hunan 410081, P.R. China
Published online on: January 5, 2016 https://doi.org/10.3892/ijo.2016.3318
Pages: 1125-1134

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Transcription factor AP-2α is involved in many types of human cancers, but its role in hepatocellular carcinogenesis is largely unknown. In this study, we found that expression of AP-2α was low in 40% of human hepatocellular cancers compared with adjacent normal tissues by immunohistochemical analysis. Moreover, AP-2α expression was low or absent in hepatocellular cancer cell lines (HepG2, Hep3B, SMMC-7721 and MHHC 97-H). Human liver cancer cell lines SMMC-7721 and Hep3B stably overexpressing AP-2α were established by lentiviral infection and puromycin screening, and the ectopic expression of AP-2α was able to inhibit hepatocellular cancer cell growth and proliferation by cell viability, MTT assay and liquid colony formation in vitro and in vivo. Furthermore, AP-2α overexpression decreased liver cancer cell migration and invasion as assessed by wound healing and Transwell assays, increasing the sensitivity of liver cancer cells to cisplatin analyzed by MTT assays. Also AP-2α overexpression suppressed the sphere formation and renewed the ability of cancer stem cells. Finally, we found that AP-2α is epigenetically modified and modulates the levels of phosphorylated extracellular signal-regulated protein kinase (ERK), β-catenin, p53, EMT, and CD133 expression in liver cancer cell lines. These results suggested that AP-2α expression is low in human hepatocellular cancers by regulating multiple signaling to affect hepatocellular cancer cell growth and migration. Therefore, AP-2α might represent a novel potential target in human hepatocellular cancer therapy.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA and Giulini SM: Early and late recurrence after liver resection for hepatocellular carcinoma: Prognostic and therapeutic implications. Ann Surg. 243:229–235. 2006. View Article : Google Scholar : PubMed/NCBI
3	Forner A, Hessheimer AJ, Isabel Real M and Bruix J: Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol. 60:89–98. 2006. View Article : Google Scholar : PubMed/NCBI
4	Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, Eskelinen M and Kosma VM: Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer. 40:1485–1495. 2004. View Article : Google Scholar : PubMed/NCBI
5	Pellikainen JM and Kosma VM: Activator protein-2 in carcinogenesis with a special reference to breast cancer - a mini review. Int J Cancer. 120:2061–2067. 2007. View Article : Google Scholar : PubMed/NCBI
6	Ropponen KM, Kellokoski JK, Lipponen PK, Pietiläinen T, Eskelinen MJ, Alhava EM and Kosma VM: p22/WAF1 expression in human colorectal carcinoma: Association with p53, transcription factor AP-2 and prognosis. Br J Cancer. 81:133–140. 1999. View Article : Google Scholar : PubMed/NCBI
7	Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L and Bar-Eli M: Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res. 64:631–638. 2004. View Article : Google Scholar : PubMed/NCBI
8	Schwartz B, Melnikova VO, Tellez C, Mourad-Zeidan A, Blehm K, Zhao YJ, McCarty M, Adam L and Bar-Eli M: Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene. 26:4049–4058. 2007. View Article : Google Scholar : PubMed/NCBI
9	Tellez C, McCarty M, Ruiz M and Bar-Eli M: Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem. 278:46632–46642. 2003. View Article : Google Scholar : PubMed/NCBI
10	Zeng YX, Somasundaram K and el-Deiry WS: AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet. 15:78–82. 1997. View Article : Google Scholar : PubMed/NCBI
11	Bar-Eli M: Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res. 14:78–85. 2001. View Article : Google Scholar : PubMed/NCBI
12	Huang S, Jean D, Luca M, Tainsky MA and Bar-Eli M: Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J. 17:4358–4369. 1998. View Article : Google Scholar : PubMed/NCBI
13	Anttila MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjänen K and Kosma VM: Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer. Br J Cancer. 82:1974–1983. 2000.PubMed/NCBI
14	Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN and Bar-Eli M: Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res. 11:267–272. 2005.PubMed/NCBI
15	Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM and Kosma VM: Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol. 16:3584–3591. 1998.PubMed/NCBI
16	Lipponen P, Aaltomaa S, Kellokoski J, Ala-Opas M and Kosma V: Expression of activator protein 2 in prostate cancer is related to tumor differentiation and cell proliferation. Eur Urol. 37:573–578. 2000. View Article : Google Scholar : PubMed/NCBI
17	Ropponen KM, Kellokoski JK, Pirinen RT, Moisio KI, Eskelinen MJ, Alhava EM and Kosma VM: Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation. J Clin Pathol. 54:533–538. 2001. View Article : Google Scholar : PubMed/NCBI
18	Ding X, Yang Z, Zhou F, Wang F, Li X, Chen C, Li X, Hu X, Xiang S and Zhang J: Transcription factor AP-2α regulates acute myeloid leukemia cell proliferation by influencing Hoxa gene expression. Int J Biochem Cell Biol. 45:1647–1656. 2013. View Article : Google Scholar : PubMed/NCBI
19	Oyama N, Takahashi H, Tojo M, Iwatsuki K, Iizuka H, Nakamura K, Homma Y and Kaneko F: Different properties of three isoforms (alpha, beta, and gamma) of transcription factor AP-2 in the expression of human keratinocyte genes. Arch Dermatol Res. 294:273–280. 2002. View Article : Google Scholar : PubMed/NCBI
20	Bennett KL, Romigh T and Eng C: AP-2alpha induces epigenetic silencing of tumor suppressive genes and microsatellite instability in head and neck squamous cell carcinoma. PLoS One. 4:e69312009. View Article : Google Scholar : PubMed/NCBI
21	Stabach PR, Thiyagarajan MM, Woodfield GW and Weigel RJ: AP2alpha alters the transcriptional activity and stability of p53. Oncogene. 25:2148–2159. 2006. View Article : Google Scholar
22	Shi D, Xie F, Zhang Y, Tian Y, Chen W, Fu L, Wang J, Guo W, Kang T, Huang W, et al: TFAP2A regulates nasopharyngeal carcinoma growth and survival by targeting HIF-1α signaling pathway. Cancer Prev Res (Phila). 7:266–277. 2014. View Article : Google Scholar
23	Li Q and Dashwood RH: Activator protein 2alpha associates with adenomatous polyposis coli/beta-catenin and Inhibits beta-catenin/T-cell factor transcriptional activity in colorectal cancer cells. J Biol Chem. 279:45669–45675. 2004. View Article : Google Scholar : PubMed/NCBI
24	Wajapeyee N, Britto R, Ravishankar HM and Somasundaram K: Apoptosis induction by activator protein 2alpha involves transcriptional repression of Bcl-2. J Biol Chem. 281:16207–16219. 2006. View Article : Google Scholar : PubMed/NCBI
25	Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, Zhou C and Zhou J: A miR-200b/200c/429-binding site polymorphism in the 3′ untranslated region of the AP-2α gene is associated with cisplatin resistance. PLoS One. 6:e290432011. View Article : Google Scholar
26	Wajapeyee N, Raut CG and Somasundaram K: Activator protein 2alpha status determines the chemosensitivity of cancer cells: Implications in cancer chemotherapy. Cancer Res. 65:8628–8634. 2005. View Article : Google Scholar : PubMed/NCBI
27	Douglas DB, Akiyama Y, Carraway H, Belinsky SA, Esteller M, Gabrielson E, Weitzman S, Williams T, Herman JG and Baylin SB: Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer. Cancer Res. 64:1611–1620. 2004. View Article : Google Scholar : PubMed/NCBI
28	Li M, Li X, Wang E and Luo E: Upregulation of Toll-like receptor 2 gene expression by acetylation of AP-2 alpha in THP-1 cells, a human monocytic cell line. Int J Biochem Cell Biol. 45:1594–1599. 2013. View Article : Google Scholar : PubMed/NCBI
29	Ding X, Zhou F, Wang F, Yang Z, Zhou C, Zhou J, Zhang B, Yang J, Wang G, Wei Z, et al: Eps8 promotes cellular growth of human malignant gliomas. Oncol Rep. 29:697–703. 2013.
30	Chen C, Liang Z, Huang W, Li X, Zhou F, Hu X, Han M, Ding X and Xiang S: Eps8 regulates cellular proliferation and migration of breast cancer. Int J Oncol. 46:205–214. 2015.
31	Ding X, Fan C, Zhou J, Zhong Y, Liu R, Ren K, Hu X, Luo C, Xiao S, Wang Y, et al: GAS41 interacts with transcription factor AP-2beta and stimulates AP-2beta-mediated transactivation. Nucleic Acids Res. 34:2570–2578. 2006. View Article : Google Scholar : PubMed/NCBI
32	Li X, Chen C, Wang F, Huang W, Liang Z, Xiao Y, Wei K, Wan Z, Hu X, Xiang S, et al: KCTD1 suppresses canonical Wnt signaling pathway by enhancing β-catenin degradation. PLoS One. 9:e943432014. View Article : Google Scholar
33	Shekhani MT, Jayanthy AS, Maddodi N and Setaluri V: Cancer stem cells and tumor transdifferentiation: Implications for novel therapeutic strategies. Am J Stem Cells. 2:52–61. 2013.PubMed/NCBI
34	Lobo NA, Shimono Y, Qian D and Clarke MF: The biology of cancer stem cells. Annu Rev Cell Dev Biol. 23:675–699. 2007. View Article : Google Scholar : PubMed/NCBI
35	Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, Ng IO, Man K, To KF, Lai PB, et al: CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology. 55:807–820. 2012. View Article : Google Scholar
36	Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
37	Cui J, Dong BW, Liang P, Yu XL and Yu DJ: Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. World J Gastroenterol. 10:1533–1536. 2004. View Article : Google Scholar : PubMed/NCBI
38	Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 129:199–221. 2003.PubMed/NCBI
39	Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR III and Nusse R: Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature. 423:448–452. 2003. View Article : Google Scholar : PubMed/NCBI
40	Wong CM, Fan ST and Ng IO: beta-Catenin mutation and over-expression in hepatocellular carcinoma: Clinicopathologic and prognostic significance. Cancer. 92:136–145. 2001. View Article : Google Scholar : PubMed/NCBI
41	Zeng G, Apte U, Cieply B, Singh S and Monga SP: siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia. 9:951–959. 2007. View Article : Google Scholar : PubMed/NCBI
42	Soussi T and Béroud C: Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 1:233–240. 2001. View Article : Google Scholar
43	McPherson LA, Loktev AV and Weigel RJ: Tumor suppressor activity of AP2alpha mediated through a direct interaction with p53. J Biol Chem. 277:45028–45033. 2002. View Article : Google Scholar : PubMed/NCBI
44	Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
45	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
46	Thomas GJ, Lewis MP, Hart IR, Marshall JF and Speight PM: AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer. 92:641–650. 2001. View Article : Google Scholar : PubMed/NCBI